Physician profile
David Fell
NPI 1962990556
$6,751.83
in general payments reported to CMS, 2019-2025
15 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2022: $457 · 2023: $3,783 · 2024: $713 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Travel and Lodging: $2,191 · Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.72 |
| Travel and Lodging | $2,190.90 |
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,084.39 | 2023-2025 | Stellaris Elite, Stellaris, Xipere |
| Alcon Vision LLC | $1,481.39 | 2023-2025 | Constellation, Unity |
| Apellis Pharmaceuticals, INC. | $423.63 | 2023-2024 | Syfovre |
| Abbvie INC. | $370.96 | 2023-2025 | |
| Regeneron Pharmaceuticals, INC. | $277.42 | 2023-2024 | Eylea Hd |
| Heidelberg Engineering, INC. | $204.63 | 2022 | |
| Alimera Sciences, INC. | $162.64 | 2022-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $153.31 | 2023 | |
| Omeros Corporation | $124.99 | 2019 | |
| Astellas Pharma US INC | $121.77 | 2023 | Izervay |
| Allergan, INC. | $99.99 | 2019 | |
| Genentech USA, INC. | $85.45 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $30.26 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $16.71 | 2022 | |
| Merck Sharp & Dohme LLC | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.